MedTrace Logo

CAYA Cancer Retrospective Cohort Study

NCT07246213 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 18000

Last updated 2025-12-19

No results posted yet for this study

Summary

Despite advances in cancer treatment, significant disparities in outcomes persist between high-income countries (HICs) and low-and middle-income countries (LMICs). Around 80% of children with cancer live in LMICs, where they face challenges such as delayed diagnosis, misdiagnosis, comorbidities, distance to treatment, financial barriers, and limited access to risk-adapted therapies.

Acute lymphoblastic leukemia(ALL)/lymphoblastic lymphoma(LBL), for example, is one of the greatest success stories in pediatric oncology, however, such improvements are not evenly distributed worldwide, and the outcomes for leukemia patients are poorer in LMICs compared to HICs, primarily due to reduced access to quality healthcare.

This study aims to assess cancer treatment outcomes in LMICs, focusing on acute lymphoblastic leukemia/lymphoblastic lymphoma. The findings will inform future studies to implement evidence-based interventions that improve care quality and reduce treatment failures through targeted strategies.

Conditions

  • Acute Lymphoblastic Leukemia
  • Lymphoblastic Lymphoma
  • Young Adult Cancer
  • Adolescent Cancer
  • Childhood Cancers
  • Acute Lymphoblastic Leukemia (ALL)
  • Lymphoblastic Lymphoma (LBL)

Interventions

OTHER

Retrospective Medical Record Review

This study involves retrospective review of medical records of pediatric, adolescent, and young adult cancer patients (ages 0-21 years) treated at participating oncology centers in Guatemala, Honduras, El Salvador, Armenia, and Tanzania. No experimental drug, device, or behavioral intervention is being administered. Data abstraction will be performed to assess treatment failure, therapy-related toxicities, and clinical outcomes.

Sponsors & Collaborators

  • Servier Affaires Médicales

    collaborator INDUSTRY

  • Resonance, Inc.

    lead OTHER

Eligibility

Min Age
0 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-04
Primary Completion
2028-06-04
Completion
2028-12-04

Countries

  • Armenia
  • El Salvador
  • Guatemala
  • Honduras

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07246213 on ClinicalTrials.gov